Health Canada Issues Recalls of Jamp Pharma`s Digoxin
Health Canada Issues recall of JAMP Pharma`s Rabeprazole
Health Canada Issues Recall of JAMP Pharma`s JAMP TELMISARTAN-HCT Tablet
Health Canada Issues Recall of JAMP Guanfacine XR 1 mg: Foreign tablets
BOUCHERVILLE, QC, May 16, 2023 /CNW/ - The JAMP Pharma Group, a Canadian pharmaceutical company based in the Montreal region, is pleased to announce the launch of PrJAMP Dapagliflozin, a generic alternative to the reference product Forxiga® d'Astrazeneca Canada Inc. PrJAMP Dapagliflozin is indicated for a use as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes for whom metformin is inappropriate due to contraindications or intolerance. When the actual treatment, associated with a diet and exercise do not result in adequate glycemic control, PrJAMP Dapagliflozin is also indicated in combination with metformin, a sulfonylurea, metformin and a sulfonylurea, sitagliptin (alone or with metformin) or insulin (alone or with metformin)2.
Health Canada Issues Recall of Jamp Pharma`s Acetaminophen 325mg Tablet
Health Canada Issues Recall of Jamp Pharma`s Acetylsalicylic Acid Tablet
Health Canada Issues Recall of Jamp Pharma`s Adalimumab injection
Health Canada Issues Recall of JAMP Pharma`s Jamp-Calcium + Vitamin D 1000 IU
Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and the JAMP Pharma Group (JAMP Pharma), a Canadian owned pharmaceutical company headquartered in the Montreal area, announced that the companies have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech, by adding two biosimilar candidates from Alvotech’s pipeline: AVT16 a biosimilar for an immunology product and AVT33, a biosimilar for an oncology product.